Search | IOVS | ARVO Journals

Showing 1 – 20 of 66

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

TL-925, a First-in-Class, Topical, Bruton’s Tyrosine Kinase Inhibitor (BTKi) in Subjects (Subjs) with Moderate to Severe Dry Eye Disease (DED)

George W Ousler; David Wirta; Blake Simmons; William Whitson; Abdoulaye Sene; Christine Wichems; Jeff Issacson; John Hai Ming Mei; Jesse McGreivy; Michael Weiser; Wayne Rothbaum; Gail Torkildsen

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2965.

ARVO Annual Meeting Abstract June 2024

PLL-g-PEG eye drops in chronic dry eye patients: results from a one-month clinical trial including a controlled adverse environment chamber

David Maxwell Kleinman; Jason Chin; Stephanie Charlotte Jones; Mark Mitchnick; Kevin Sill; Matthew Chapin; George W Ousler

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2974.

ARVO Annual Meeting Abstract June 2024

Does an Ocular Lubricant with Hydroxypropyl Guar and Sodium Hyaluronate Prolong Maintenance of Best Corrected Visual Acuity, Measured Objectively by the Interblink Visual Acuity Test in Dry Eye Disease Patients?

Jason Chin; Stephanie Jones; Ethan bensinger; George W Ousler

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2963.

ARVO Annual Meeting Abstract June 2024

Factors Affecting Screen Failures in Clinical Trials for Dry Eye Therapies

Samantha Kerti; John David Rodriguez; Adam Hamm; Leslie O'Dell; George W Ousler; Gustavo De Moraes; Mark B Abelson

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2954.

ARVO Annual Meeting Abstract June 2024

Measuring Palpebral Fissure Height in Real Time for Personalizing Airflow within Ora’s Controlled Adverse Environment 2.0

Ethan bensinger; Reza Hojjaty Saeedy; Immanuel Dorneich; George W Ousler; Adam Hamm; Leslie O'Dell; Matthew Chapin; Gustavo De Moraes; Mark B Abelson

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2953.

ARVO Annual Meeting Abstract June 2024

A Comparison of Lissamine Green Staining vs Schirmer Test in a Dry Eye Subject Population

Leslie O'Dell; Samantha Kerti; Mark B Abelson; George W Ousler

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2939.

ARVO Annual Meeting Abstract June 2024

Comparison study methods between Paper Visual Analog Scale (VAS) and Electronic Visual Analog Scale (VAS) Questionnaires for use in Clinical and Virtual Trials

Sadie Burnham; Ethan bensinger; Adam Hamm; Gustavo De Moraes; Leslie O'Dell; George W Ousler; Mark B Abelson

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2928.

ARVO Annual Meeting Abstract June 2023

Repairing the Corneal Nerve Bed using Collagen Mimetic Peptides

Lauren K Wareham; Joseph Holden; Olivia Bossardet; Robert O. Baratta, MD; Brian J Del Buono; Eric Schlumpf; George W Ousler; David J Calkins

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):716.

ARVO Annual Meeting Abstract June 2023

Effectiveness of PL9643 in treating the signs and symptoms of moderate to severe dry eye disease including a subpopulation of hyper-responders to CAE ® challenge: results from 2 independent clinical trials

George W Ousler; Robert Jordan; Carl Spana

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3969.

ARVO Annual Meeting Abstract June 2022

Melanocortin agonist PL9643 significantly improves ocular signs and symptoms of moderate to severe dry eye disease (DED), including tear film break up time (TFBUT)

David Evans; Kenneth Kenyon; George W Ousler; Michael Watson; Patrick Vollmer; Eugene B. ` McLaurin; Gail Torkildsen; Jason Winters; John Dodd; Robert Jordan; Stephen Wills; Carl Spana

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1563 – A0288.

ARVO Annual Meeting Abstract June 2022

Safety and efficacy of ophthalmic mitochondrial reactive oxygen species scavenger Visomitin for the treatment of dry eye disease: findings of VISTA-1 and VISTA-2 studies

George W Ousler; Michael Watson; John D Sheppard; Paul Karpecki; Lawrence T. Friedhoff; Anton Petrov; Maxim Skulachev; Malcolm Ngiam; Quinn Xue

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1555 – A0280.

ARVO Annual Meeting Abstract June 2022

Dry eye sign, symptom and quality of life improvements associated with administration of AR-15512

David Wirta; Michelle Senchyna; David G. Evans; Eugene B. ` McLaurin; George W Ousler; Amber E. Lewis; David Hollander

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1513 – A0238.

ARVO Annual Meeting Abstract June 2021

Topical BRM421 Ophthalmic Solution improves signs and symptoms of moderate to severe dry eye patients in clinical trials

Ping-Yen Huang; Yeou-Ping Tsao; Conrad Tou; Frank Lee; George W Ousler; Blair Boehmer; Eugene B McLaurin; Gail Torkildsen; David Wirta; Tsung-Chuan Ho; Hsiao-Han Wang; Erin Chang; Sheng-Shin Wang; Shih-Ya Chang; Yilun Chiang; Haishan Jang

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1335.

ARVO Annual Meeting Abstract June 2021

Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects With Dry Eye Disease

Kenneth Kenyon; George W Ousler; Michael Watson; Gail Torkildsen; Patrick Vollmer; Eugene B McLaurin; David Evans; Jason Winters; John Dodd; Robert Jordan; Stephen Wills; Carl Spana

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1333.

ARVO Annual Meeting Abstract June 2021

Topline Results From a Multicenter, Open-label, Phase 4 Study of Repository Corticotropin Injection in Patients With Treatment-resistant Severe Non-infectious Keratitis

Joseph Grieco; Eugene B McLaurin; George W Ousler; Jingyu Liu; Oktay Kacmaz; David Wirta

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1275.

ARVO Annual Meeting Abstract June 2021

Prevalence of hyper-response to CAE challenge in dry eye disease

George W Ousler; Michael Watson; Divya Narayanan; Garrick Wallstrom

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1272.

ARVO Annual Meeting Abstract June 2021

Comparing Schirmer’s test with other clinical outcomes in dry eye

Jeffrey Gemi; Michael Watson; Divya Narayanan; George W Ousler

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1271.

ARVO Annual Meeting Abstract June 2021

Relationship Between Dry Eye Symptoms and Aging

Seth Miller; Michael Watson; Divya Narayanan; George W Ousler

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1269.

ARVO Annual Meeting Abstract June 2020

Collagen Mimetic Peptides (CMPs) as a bioengineering tool to repair damaged collagen substrates and basement membranes and facilitate corneal epithelial growth

Robert O. Baratta, MD; George W Ousler; Brian Del Buono, Ph.D.; David J. Calkins, Ph.D.; Brian P Ceresa

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):173.

ARVO Annual Meeting Abstract July 2019

Safety and Efficacy of First-in-Class mtROS scavenger SkQ1 for the Treatment of Dry Eye Disease: A Phase 3 Clinical Trial

Lawrence Tim Friedhoff; Anton Petrov; George W Ousler; Michael Watson; Qi Xue; Malcolm Ngiam

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6750.

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

TL-925, a First-in-Class, Topical, Bruton’s Tyrosine Kinase Inhibitor (BTKi) in Subjects (Subjs) with Moderate to Severe Dry Eye Disease (DED)

PLL-g-PEG eye drops in chronic dry eye patients: results from a one-month clinical trial including a controlled adverse environment chamber

Does an Ocular Lubricant with Hydroxypropyl Guar and Sodium Hyaluronate Prolong Maintenance of Best Corrected Visual Acuity, Measured Objectively by the Interblink Visual Acuity Test in Dry Eye Disease Patients?

Factors Affecting Screen Failures in Clinical Trials for Dry Eye Therapies

Measuring Palpebral Fissure Height in Real Time for Personalizing Airflow within Ora’s Controlled Adverse Environment 2.0

A Comparison of Lissamine Green Staining vs Schirmer Test in a Dry Eye Subject Population

Comparison study methods between Paper Visual Analog Scale (VAS) and Electronic Visual Analog Scale (VAS) Questionnaires for use in Clinical and Virtual Trials

Repairing the Corneal Nerve Bed using Collagen Mimetic Peptides

Effectiveness of PL9643 in treating the signs and symptoms of moderate to severe dry eye disease including a subpopulation of hyper-responders to CAE ® challenge: results from 2 independent clinical trials

Melanocortin agonist PL9643 significantly improves ocular signs and symptoms of moderate to severe dry eye disease (DED), including tear film break up time (TFBUT)

Safety and efficacy of ophthalmic mitochondrial reactive oxygen species scavenger Visomitin for the treatment of dry eye disease: findings of VISTA-1 and VISTA-2 studies

Dry eye sign, symptom and quality of life improvements associated with administration of AR-15512

Topical BRM421 Ophthalmic Solution improves signs and symptoms of moderate to severe dry eye patients in clinical trials

Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects With Dry Eye Disease

Topline Results From a Multicenter, Open-label, Phase 4 Study of Repository Corticotropin Injection in Patients With Treatment-resistant Severe Non-infectious Keratitis

Prevalence of hyper-response to CAE challenge in dry eye disease

Comparing Schirmer’s test with other clinical outcomes in dry eye

Relationship Between Dry Eye Symptoms and Aging

Collagen Mimetic Peptides (CMPs) as a bioengineering tool to repair damaged collagen substrates and basement membranes and facilitate corneal epithelial growth

Safety and Efficacy of First-in-Class mtROS scavenger SkQ1 for the Treatment of Dry Eye Disease: A Phase 3 Clinical Trial

To View More...

You must be signed into an individual account to use this feature.